MUMBAI (Reuters) - Sun Pharmaceutical Industries Ltd , India's top drugmaker by market value, reported a net loss of 12.76 billion rupees for the June quarter, due to a provision for settling a patent suit, it said on Friday.
The Mumbai-based company said net sales rose 31 percent to 34.82 billion rupees for the first quarter ended June 30.
Sun Pharma, along with Teva Pharmaceuticals Industries Ltd , has to pay Pfizer Inc $2.15 billion to settle a patent suit related to marketing generic versions of its acid-reflux drug Protonix.
(Reporting by Prashant Mehra; Editing by Prateek Chatterjee)